Sol-Gel Technologies Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
0.7%projected annual EPS growth
Analyst Coverage
3analysts covering
Monitoring Framework
Key Performance Indicators
SGT-610 Phase 3 Clinical Trial Progress QuarterlyTarget: Top-line results expected in Q4 2026
Cash Runway and Liquidity Balance Quarterly10.1MTarget: Fund operations into Q1 2028
Annual Royalty Revenue Stream from Ex-U.S. Partnerships AnnuallyTarget: Approximately $10 million by 2031
Watch Items
- SGT-610 Phase 3 Top-line Data ReleaseTrigger: Unblinding and reporting of top-line results in Q4 2026Action: Evaluate clinical efficacy, safety profile, and prepare for FDA NDA submission if positive.
- Commercial Launches of TWYNEO and EPSOLAY in Partnered TerritoriesTrigger: Launches expected in 2027 (EPSOLAY) and 2028 (TWYNEO)Action: Monitor partner launch timelines, commercial execution, and initial royalty inflows.
- SGT-610 Proof-of-Concept Study in High-Frequency Basal Cell Carcinoma (HF-BCC)Trigger: Initiation of feasibility/proof-of-concept studyAction: Assess clinical rationale and design parameters for a potential Phase 3 trial in 2027.
Research as of 19 Jun 2026